Inhibrx Inc
INBX
Market Cap$1.79B
Close$
$1.31
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.79 Billion |
|---|---|
| Enterprise Value | $1.72 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.12 |
| Beta | 0.0 |
| Outstanding Shares | 52,278,007 |
| Avg 30 Day Volume | 381,050 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.4 |
|---|---|
| PEG | -5.74 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 954.17 |
| Enterprise Value to EBIT | -7.83 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 4.83 |
Revenue Sources
No data
ESG Score
No data
About Inhibrx Inc
88 employeesInhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...